Search

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

Parnaparin

Parnaparin is an heparin of low molecular weight with antithrombotic effects.

Anacaulase

It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides … Removing eschar (a process also known as debridement) through surgical procedures can lead to significant trauma, major blood and heat loss and adjacent tissue damage.

Trestolone

Trestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods. … In males, regular administration of sufficient quantities of trestolone induces a state of temporary infertility.

Curcumin sulfate

trans NV-04

trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

Thymol

A phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. … It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)

Padimate A

Padimate A is an ester derivative of PABA and an ingredient in some sunscreens. … It absorbs ultraviolet rays thereby preventing sunburn, however, its chemical structure and behaviour is similar to an industrial free radical generator.

Trospium

[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.

Bebtelovimab

Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.